A phase II study evaluating the safety and efficacy of ENV-101 (taladegib) in patients with advanced solid tumors harboring PTCH1 loss of function mutations (ESMO 2022) - Jul 28, 2022 - Abstract #495TiP; Pres time: Sep 10, 2022; Location: Poster Area, Hall 4; P2 | "Stage 1 (phase IIa) of this protocol will enroll a total of 44 patients randomized between two dose levels. In the presence of acceptable efficacy, stage 2 (phase IIb) of this protocol will expand enrollment using a single dose level."
Clinical • P2 data • Basal Cell Carcinoma • Bladder Cancer • Brain Cancer • Breast Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Lung Cancer • Medulloblastoma • Melanoma • Neuroendocrine Tumor • Non-melanoma Skin Cancer • Oncology • Oral Cancer • Pancreatic Cancer • Prostate Cancer • Rhabdomyosarcoma • Sarcoma • Small Cell Lung Cancer • Solid Tumor • Urothelial Cancer • PTCH1 • SMO
|
|
J.J. Luke1; S. Pendyala2; A. Di Francesco3; S. Kim3; L. Dellamary4; S. KC4; H. Humphreys3; M. De Los Rios3; J. Pitman3; J. Hood3; D.S. Hong5
|